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Summary As a promoter of angiogenesis, vascular endothelial growth factor (VEGF) is believed to play a pivotal role in tumour growth and
metastasis. The aim of this study was to determine the value of preoperative serum VEGF levels in the early diagnosis of ovarian cancer and
in the differential diagnosis of adnexal masses. We examined preoperative serum VEGF levels in healthy women (n = 131), patients with
benign ovarian cysts (n = 81) and in ovarian cancer patients (n = 44) by using an ELISA (R&D Systems, Minneapolis, MN, USA). A logistic
regression model was carried out to determine the influence of VEGF and CA 125 on the probability of malignancy. VEGF revealed a
significant influence on the odds of presenting with malignancy vs healthy women (P= 0.001). At 363.7 pg ml-', VEGF achieved a sensitivity
of 54% and a specificity of 77%. With respect to the differentiation between benign cysts and ovarian cancer, CA 125 (P < 0.0001) but not
VEGF (P= 0.229) predicts the presence of malignancy in a multivariate model. In conclusion, VEGF does not appear to be a useful tool in the
early diagnosis of ovarian cancer or for indicating the absence or presence of malignancy in patients with an adnexal mass.
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Angiogenesis, the formation of new blood vessels, is considered
essential for wound healing, placental growth, the female repro-
ductive system and the growth and metastasis of solid malignant
tumours (Folkman, 1995). Angiogenic factors are soluble mole-
cules released by the tumour itselfand are able to induce an angio-
genic response. This implies that (a) the inhibition of angiogenic
factors would result in a suppression oftumour growth and metas-
tases (Ke-Lin et al, 1996; Melnyk et al, 1996) and (b) the detection
of angiogenic factors may indicate the presence of a malignant
tumour at an early stage. While a variety ofgrowth factors exhibit
angiogenic activity, there is strong evidence for a pivotal role of
VEGF in tumour angiogenesis. Vascular endothelial growth factor
(VEGF), which is also known as vascular permeability factor
(VPF), stimulates angiogenesis by increasing vascular perme-
ability (Senger et al, 1983) and by acting as an endothelial cell
mitogen (Ferrara and Heinzel, 1989). VEGFis a dimeric glycopro-
tein with four spliced variants consisting of 121, 165, 189 and 206
amino acid residues expressing almost identical biological activi-
ties by binding to specific class III receptor tyrosine kinases (flt-l
and KDR) (Neufeld et al, 1996; Terman and Dougher-Vermazen,
1996). Recently, Guidi et al (1995) and our group (Bancher-
Todesca et al, 1997; Obermair et al, 1997) reported that the pres-
ence of VEGF is associated with neoplastic transformation in
cervical (CIN) and in vulvar intraepithelial neoplasia (VIN),
suggesting that increasing VEGF may represent an early event in
the carcinogenic process.
Received 24 July 1997
Revised 13 November 1997
Accepted 19 November 1997
Correspondence to: A Obermair
Over the years, mortality resulting from ovarian cancer has
remained at a relatively high level because the vast majority of
patients present with advanced stage ofdisease. The availability of
a marker indicating early-stage ovarian cancer would represent a
highly specific test forearly diagnosis ofovarian cancer and might
help to reduce mortality secondary to ovarian cancer. The value of
tumour antigen CA 125 forthe early diagnosis ofovarian cancer in
premenopausal women is limited because non-malignant condi-
tions such as endometriosis or infections are also associated with
increasing serum levels of CA 125 (Jacobs and Bast, 1989; Oram
and Jeyarajah, 1994). However, even in post-menopausal women,
the value of serum CA 125 level for early diagnosis of ovarian
cancer is under investigation because it is elevated in a significant
number ofpatients with early-stage disease (Jacobs et al, 1996).
The aim of the present study was to compare preoperative
serum levels of VEGF and the tumour marker CA 125 in healthy
patients, in patients with benign ovarian cysts and in ovarian carci-
noma patients, with regard to their value in the early diagnosis of
ovarian cancer or in the differential diagnosis ofthe adnexal mass.
Furthermore, it was of interest to find out whether a combination
of VEGF with CA 125 was superior to the determination of a
single CA 125 tumour marker with regard to early diagnosis of
ovarian cancer and differential diagnosis of adnexal masses
suspected for ovarian cancer.
MATERIALS AND METHODS
Patients
Clinical data were obtained from files at the University Hospital of
Vienna, Department of Gynecology and Obstetrics. Peripheral
venous blood samples were taken from a total of 256 patients:
healthy women (n = 131); patients who underwent unilateral
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Figure 1 Box plots of preoperative serum VEGF levels in healthy women
(n = 131), in patients who had unilateral oophorectomy for a benign ovarian
cyst (n = 81) and in ovarian cancer patients (n = 44). The bottom and top
edges of the box are located at the sample 25th and 75th percentiles. The
central vertical lines, called whiskers, extend from the box to a distance of at
most 1.5 interquartile ranges. Any value more extreme than this is marked
with a zero if it is within three interquartile ranges of the box, or with an asterix
(*) if it is still more extreme
ovarectomy for suspected ovarian cancerbut in whom histological
examination revealed non-malignant (benign) ovarian cysts (n =
81); patients who underwent total abdominal hysterectomy, bilat-
eral salpingo-oophorectomy, lymph node dissection and omentec-
tomy for epithelial ovarian cancer (n = 44). The mean age of the
entire patient population was 47 years (range 21-79 years).
Histological review was carried out in accordance with the WHO
criteria (Serov et al, 1973). The stage of disease was classified
according to the International Federation of Gynecology and
Obstetrics (FIGO, 1987). Blood samples were taken preopera-
tively and assayed for CA125 within 1 week of surgery using an
immunoradiometric assay (Abbott CA 125 RIA Diagnostic Kit,
Abbot Laboratories, North Chicago, IL, USA).
VEGF immunoassay
The patients' blood was obtained 24-48 h preoperatively by
venous punctuation and was immediately centrifuged at 2500gfor
15 min. The serum was frozen at-20°C until examination. For the
measurement ofVEGF in serum, acommercially available ELISA
was used (Quantikine Human VEGF Immunoassay; R&D
Systems). Briefly, samples were incubated in duplicates (100 ul)
in microtitre plates precoated with a monoclonal antibody specific
for VEGF at room temperature for 2 h. After washing away any
unbound substances, an enzyme-linked polyclonal antibody
specific for VEGF was added. After incubation at room tempera-
ture for 2 h and washing, a substrate solution was added. Colour
development was stopped after 20 min at room temperature and
the intensity of the colour was read at 450 nm within 30 min.
Results were calculated from a standard curve (recombinant
human VEGF165; range 31.2-2000 pg ml-') generated by a four-
parameterlogistic curve-fit and expressed in pg mll ofserum. The
assay has been reported to recognize both natural human VEGF
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Figure 2 Receiver operator characteristics (ROC) curves comparing
(A) healthy women (n = 131) and ovarian cancer patients (n = 44) with
respect to their preoperative serum VEGF levels and (B) patients with benign
ovarian cysts (n = 81) and ovarian cancer patients (n = 44) with respect to
their serum VEGF and CA 125 levels. Univariate logistic regression models
for VEGF --- -), CA 125 (-) and simultaneous consideration of both
varables (--) in a multivariate model
and recombinant VEGF and not to exhibit cross-reactivity with a
series ofcytokines and growth factors. The manufacturer claims a
sensitivity of less than 9.0 pg ml-' and an intra- and interassay
variation ofless than 10%.
Statistical methods
Because of their skewed distribution, median values (range) are
given to describe VEGF and serum CA 125 levels. Logarithmic
transformed values were used forfurther analysis. Logistic regres-
sion models (Hosmer and Lemeshow, 1989) were used to analyse
theinfluence ofVEGFand serumCA 125 levels on the probability
of malignancy. Using the logistic regression models, sensitivity
and specificity were calculated for each possible threshold value
of the estimated probability for malignancy. Based on these
values, receiver operator characteristic (ROC) curves (Campbell
and Machin, 1995) were constructed to visualize the relationship
between VEGF and CA 125, and malignancy. One univariate
logistic regression model was used to compare healthy women
with ovarian cancer patients in respect of their VEGF values. The
British Journal ofCancer(1998) 77(11), 1870-1874
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Figure 3 Plot of serum VEGF vs CA 125 levels (log-transformed values)
with respect to their potential to predict the presence of malignancy. The dots
represent patients with a malignant ( 0 0, n = 44) or benign (O 0 0,
n = 81) adnexal mass. Note that increased serum CA 125 levels but not
VEGF predict the presence of malignancy
Table 1 Median serum VEGF levels according to various clinical and
histopathological parameters
Median 25-75% Quartile Kruskal-Wallis
(range) P-value
Patient age (years)
<50 284.6 133.3-462.6
(105.4-777.3) 0.87
>50 338.5 102.6-665
(64.2-283.5)
FIGO stage
1,11 387.5 133.4-665
(69.7-283.5) 0.55
III, IV 298.9 96.4-519.9
(75.8-273.3)
Grading
G1,2 247.2 102.6-582.5
(64.2-274.9) 0.044
G3 519.9 236.3-1060
(132.4-283.5)
Histological subtype
Serous, mucinous 193.6 78.6-519.9
(69.7-273.3) 0.14
Others 387.5 166.9-665
(133.4-283.5)
Residual tumour mass
Absent 379.7 180.3-519.9
(78.6-135.3) 0.71
Present 375.6 166.9-684.9
(96.4-283.5)
corresponding P-value was calculated and the ROC curve was
constructed. Univariate and multivariate logistic regression
analysis were used to compare patients with benign ovarian cysts
and ovarian cancer patients with respect to their VEGF and CA
125 values. The univariate models show the influence of each of
the two variables on the probability for malignancy without
considering the other one. Corresponding P-values were calcu-
lated and ROC curves for both models were constructed. Based on
the multivariate analysis, a third ROC curve was constructed to
show the diagnostic power oftheir simultaneous consideration. To
test whether patients could be classified more accurately by taking
into consideration VEGF values in relation to CA 125 levels, an
interaction term was included in the model. Calculations were
performed using the SAS software package (SAS Institute, 1989).
All mentioned P-values are results of two-sided tests. P-values of
less than 0.05 are considered statistically significant.
RESULTS
Serum VEGF levels and the presence of ovarian
carcinoma compared with healthy women
The overall median VEGF concentration (range) was 256.8 pg ml-l
(0-2835 pg ml-'). The median serum VEGF levels were
218.9pg ml-' (range 0-11OOpg ml') for the healthy patients,
290.8 pg ml' (69.3-719.7 pg ml-') forthebenign ovarian cyst group
and 379.7 pg ml' (64.2-2835 pg ml-') for the ovarian carcinoma
group (Figure 1). In a univariate logistic regression model, VEGF
revealed a significant influence on the odds of presenting with
malignancy vs healthy women (P = 0.001). The higher the VEGF,
the higher was the risk of malignancy. At 363.7 pg ml-', VEGF
achieved a sensitivity of54% and a specificity of77% (Figure 2A).
Serum VEGF and CA 125 levels on the presence of
ovarian carcinoma compared with benign cysts
The overall median serum CA 125 level (range) was 29.0 U ml'
(4-23100 U ml-'). Median serum CA 125 levels were 18.3 U ml'
(5.0-210 U ml-') for the benign ovarian cyst group and
352.0 U ml' (4-23100 U ml-') for the ovarian carcinoma group.
In univariate logistic regression models, CA 125 (P < 0.0001) but
not VEGF (P = 0.130) predicts the presence of malignancy as
opposed to benign cysts (Figure 3). VEGF achieved a sensitivity
of 56% and a specificity of 69% at 363.7 pg ml-', while CA 125
achieved a sensitivity of 85% and a specificity of 93% at
74.9 U ml'. In a multivariate regression model considering
serum VEGF and CA 125 levels simultaneously, only CA 125
(P <0.0001), but not VEGF (P = 0.229), revealed statistical signif-
icance. After inclusion of an interaction term, no statistically
significant improvement in the prediction of the probability of
malignancy was observed (P = 0.278) (Figure 2B).
Correlation of serum VEGF ovarian cancer levels in
ovarian cancer with serum CA 125 levels, stage of the
disease, histological subtype, histological grade and
age at the time of diagnosis
Serum VEGF levels (25-75% confidence interval) were signifi-
cantly lower in patients with high/moderate differentiated tumours
(247.2 pg ml'; 102.6-582.5 pg ml') than in those with undiffer-
entiated tumours (519.9 pg ml-'; 236.3-1060.0 pg ml') (Kruskal-
Wallis P = 0.044), whereas no correlation of VEGF serum levels
with the patient's age at diagnosis, stage of disease, histological
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type, and the extent ofresidual tumour mass afterprimary surgery
was found (Table 1). No correlation was found between preopera-
tive serum CA 125 level and serum VEGF concentration (data not
shown).
DISCUSSION
There is abundant evidence that CA 125 but not the serum VEGF
level is a relevant predictive factor to determine the presence or
absence of malignancy in patients with suspected ovarian cancer
(Figure 3).
We found significantly lower serum VEGF levels in healthy
women compared with those in women with ovarian cancer.
Although statistically significant, the ROC curves show that
VEGF does not represent a useful tool for early diagnosis of
ovarian cancer. At 363.7 pg ml', VEGF achieved a sensitivity of
54% and a specificity of 77% in our investigation (Figure 2A).
With respect to differentialdiagnosis CA 125 revealed asensitivity
of 85% and a specificity of 93% at 74.9 U ml- cut-off value.
These excellent results might partly be influenced by the fact that
our ovarian cancer population mainly consisted ofadvanced-stage
patients. However, CA 125 levels have beenrepeatedly reported to
be a useful diagnostic tool to differentiate benign from malignant
ovarian masses (Markowska et al, 1994; Woolas et al, 1995;
Gadducci et al, 1996).
While a strong correlation between CA 125 and tumour stage
was found (data not shown), no correlation was detected between
serum VEGF and the stage ofdisease in ourstudy. This mightindi-
cate that CA 125 but not VEGF may represent a late symptom in
tumour development and tumour growth. Among the 44 ovarian
cancer patients, seven presented with stage I disease. Serum CA
125 levels were 22.0 U ml-1 in two patients and higher than the
usually used cut-offvalue of35 U ml' in the other fivepatients. In
those two patients with low CA 125 levels, the corresponding
VEGF values were 105.4 pg ml-l and 180.3 pg ml-, thus also
remaining at arelatively low level. The present data therefore indi-
cate that VEGF is only weakly excreted into the serum of ovarian
cancerpatients.
Although higher VEGF values were observed in ovarian cancer
patients compared with patients with benign ovarian cysts, the
serum VEGF level did not allow prediction of malignancy. The
reason might be a large overlap of serum VEGF levels in patients
with ovarian cancer and in those who had surgery for a benign
cyst. This reasonable overlap can be explained by the fact that a
significant proportion ofpatients with benign cysts also expressed
VEGF at ahigh concentration. Anotherlikely reason forthe failure
of VEGF to match usefulness of CA 125 in the diagnosis of
ovarian cancer might be that CA 125 is largely a product of
ovarian cancer cells, whereas VEGF is a protein made during a
variety ofphysiological andnon-physiological processes. VEGFis
therefore likely to provide a high background.
Interpreting of serum VEGF levels alsodepends on the immuno-
logical methods used. The manufacturer of the kit used in this
study claims that the assay was optimized to limit the amount of
interference by non-specific factors in serum. No significant inter-
ference or cross-reactivity with various cytokines was found.
However, so far alpha-2-macroglobulin and other serum proteins
have notyet beentested, apossibleinterference resulting in epitope
masking can not be completely excluded (Soker et al, 1993).
The use of antibodies directed against N-terminus and
C-terminus synthethic oligopeptides may result in false-negative
results in the presence ofproteolytical processes or degradation of
VEGF (Yeo et al, 1992). As a result, N- or C-terminus-specific
antibodies may fail to recognize VEGF. These potential drawbacks
may be prevented by the use of polyclonal antibodies directed
against human VEGF orbacterially expressed VEGFpolypeptides.
(Kondo et al, 1994). The immunoassay applied for the aim of this
study uses antibodies raised against insect cell SF21-expressed
recombinant human VEGF165 reacting with naturally occurring
human VEGFin acomparable matter. The kit manufacturerreports
an average recovery rate of 102% from spiked serum. Considering
all characteristics ofthis kit, the possible influence ofVEGFdegra-
dation or complexing with serum proteins should be low.
Undoubtedly, VEGF plays an essential role in the growth and
metastases of ovarian cancer. Boocock et al (1995) demonstrated
that mRNA encoding VEGF, as well as VEGF receptors flt and
KDR were detected in primary ascitic cells and in three out offour
ovarian carcinoma cell lines by reverse transcriptase-polymerase
chain reaction. By means ofin situ hybridization, elevated expres-
sion of VEGF mRNA could be found in all primary tumours and
their metastases. Recently, Mattem et al (1997) found a significant
positive correlation of VEGF mRNA expression in ovarian carci-
noma tissue and tumour cell proliferation rates as assessed by
histone H3 mRNA expression. However, no association was found
between the patients' clinical course and the extent of VEGF
mRNA expression.
Although, there is abundant evidence to show that VEGF plays
a central role in the development and the growth of malignant
tumours, only scarce information is provided regarding serum
VEGF levels in tumour patients. Recently, Takano et al (1996)
reported about concentrations of VEGF in the serum and tumour
tissue of brain tumour patients. No difference in serum VEGF
concentration was found between nine patients with malignant
brain tumours of different histological types with a median serum
VEGF concentration of 40.4 pg ml-1 (range 18.4-277.0 pg ml')
and healthy volunteers (range 28.4-184.4 pg ml-'). Furthermore,
no correlation was found between VEGF concentrations in serum
and tumour extracts. In contrast, Yeo et al (1993) found elevated
levels in malignant effusions, but failed to detect VEGF in the
serum and urine obtained from patients with and without malig-
nant ascites. They explained the failure to detect VEGF in the
serum of malignant tumour patients by the clearance of VEGF
from the circulation. In fact, the serum levels of a tumour marker
are influenced by the balance of the tumour markers released into
the effluent blood and its metabolism and excretion. As the half-
life ofVEGF is known to be only a few hours, one possible expla-
nation for relatively low levels in patients with malignant tumours
could be that VEGF is rapidly metabolized and excreted. To
our knowledge, little is known about the pharmacokinetic or
pharmacodynamic characteristics ofVEGF.
Angiogenesis is normally seen in the female reproductive
system as part of ovulation, endometrial proliferation, and the
development and growth of the corpus luteum (Christenson and
Stouffer, 1996). Kamat et al (1995) found VEGF mRNA and
protein to be expressed by human ovarian granulosa and theca
cells late in follicle development and subsequent to ovulation. By
using the immunohistochemical approach, Gordon et al (1996)
found intense VEGF immunostaining within the highly vascular-
ized corpora lutea. They concluded that VEGF might contribute to
fluid formation in ovarian cysts and that it plays an important role
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in the growth and maintenance of the ovarian follicle and corpus
luteum by mediating angiogenesis. These data may indicate that
VEGF is expressed during ovarian cyst formation as well as in
neoplastic transformation.
In conclusion, our data demonstrate that VEGF may reflect
tumour burden in patients with ovarian cancer. Because ofthe low
sensitivity and specificity, VEGF does not seem to be a clinically
useful discriminator between the absence or the presence ofmalig-
nancy in patients who are intending to undergo surgery for
suspected ovarian cancer.
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